#### Vita Life Sciences Ltd

Morgan Stanley Micro Cap Conference















### Vita Life Sciences overview







- Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements
- > 750 800 registered sku of vitamins and supplements sold in 7 countries in the Asia Pacific region
- > 3 major brands
- VitaHealth: products sold in pharmacies, hospitals, clinics and health food stores throughout Southeast Asia
- Herbs of Gold: products sold in health food stores in Australia, and pharmacies in Singapore and Malaysia
- VitaScience: products sold through independent pharmacies in Australia
- Approx. 425 employees across 7 countries
- ASX listed since 2007 (ASX:VSC)

### **Vita Life Sciences Footprint**



	Population (m)	Business Commenced	2015 Revenue (A\$m)	
Australia	24	1989	15.6	
Malaysia	31	2000	14.4	
Singapore	5	1947*	6.3	
Thailand	68	2007		
China	1,379	2008	2.3	
Vietnam	92	2010		
Indonesia	258	2015		



\* As a retail pharmacy.

# Vita Life Sciences products and market channels

	VitaHealth®  Enriching Lives .Since 1947	herbs of gold  Dedicated to your health	VitaLife™	VitaScience THE SCIENCE OF HEALTHY LIVING
Country presence	Malaysia	Australia #	-	-
- At IPO (2007)	Singapore			
- Expanded (2008 +)	China	Singapore*	Malaysia	Australia
	Thailand	Malaysia*		
	Vietnam			
	Indonesia (H2 2015)			
Total no. of products (sku) on sale	~450	~200	~30	~20
Product offering				
Supplements	✓	✓	✓	✓
Vitamins	✓	✓	✓	✓
Minerals	✓	✓	✓	✓
Meal replacement	×	×	✓	×
Market channels	Health food stores & pharmacies	Health food stores# & pharmacies*	Direct to customer	Independent Pharmacies



Vita Life Sciences has built a portfolio of recognised & respected brands

### VSC has achieved its IPO strategies

The commencement of operations in Indonesia during 2015 represents a watershed moment for VSC as it has now achieved strategic goals set at IPO:



Consolidate business in 3 established countries: Australia, Malaysia and Singapore



**Expansion of marketing channels in 3 established countries** 



Expand into 4 new Asian countries with 50m+ population




Generate consistent profitability and dividends for investors




## Vita Life Sciences platform growth since IPO

#### 2008 revenue by geography

#### 2015 revenue by geography



Total revenue: \$14m




Total revenue: \$39m

Revenue has grown from both consolidation of established businesses and introduction of new market channels



### Vita Life Sciences growth since IPO





## Positioned to grow with the health conscious Asia Pacific middle class

- 1 Trusted brand portfolio
- 2 Established footprint in 7 countries
- 3 Substantial product portfolio offering 750 800 sku and growing
- Platform for sustained growth: operations established in 7 Asia Pacific countries
- Financially disciplined: Growth and expansion into 4 new Asian markets has been achieved since IPO whilst maintaining a net cash balance sheet



# VSC will leverage off established platform in next phase of lifecycle

1

#### VSC's established platform:

- Reputable brands recognised in 7 countries
- Selected 50m+ population South East Asian countries entered
- Management build out in established markets
- Managing Director to focus proven skills in building new businesses day-to-day, while overseeing established markets
- Malaysian Central facility to provide considerable benefits
- 2

Group wide, margins have stabilised at a sustainable level. VSC now focussed on revenue growth.



### Malaysia Central Facility



Malaysian central facility will increase VSC's operational capabilities:

- On-site new packing plant will enable VSC to increase customer service;
- On-site laboratory positions VSC to meet more stringent product efficacy pharmaceutical regulations associated with the inception of the ASEAN free trade agreement;
- > State of the art training centre providing an education focal point for staff and customers alike; and
- Technologically and aesthetically improved office & meeting spaces



### **Malaysia Central Facility**





## Established market objectives: Australia

- CEO of Australia, Mr Andrew O'Keefe, commenced October 2014
- Mr O'Keefe's key deliverables:
  - 1. Consolidate Herbs of Gold market position
  - 2. Introduce VitaScience brand to the marketplace and build a sustainable business
  - 3. Identify opportunities to leverage Group's position into new customer groups



# Herbs of Gold – Permeating the Asian market





# VitaScience is an exclusive brand for Australian independent pharmacies









# Established market objectives: Malaysia OTC and Singapore

- CEO of Malaysian and Singaporean established businesses, Mr Danny Tan, commenced February 2016
- Mr Tan's key deliverables are:
  - 1. Build on Vita Health market leading position brand in Singapore and Malaysia
  - 2. Introduce Herbs of Gold brand to the marketplace and build a sustainable business
  - 3. Identify opportunities to leverage Group's position into new customer groups



### New market strategies

- Operations established, however remain in their infancy
- Through management build out in established businesses, Mr Tie's extra capacity will allow him to drive the new markets:
  - China: Regulatory hurdles to be navigated
  - > Thailand: Introduction of new management team to address product positioning to changing market conditions
  - > Indonesia: Operations commenced in 2015
  - Vietnam: Expanding product line and build out of staff
  - Malaysian MLM: Upgraded training and meeting facilities in Malaysian headquarters is expected to add significantly to the stature of the MLM and attract skilled staff



### **Outlook for 2016**

- > The Company's steady growth in recent years is expected to continue in 2016
- ➢ Given the Company's diverse operating platform the Directors intend to provide more detailed guidance mid way through the year



#### Disclaimer

This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "may", "assume" and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct, Except for any statutory liability which cannot be excluded, Vita Life and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life since the date of this presentation.



#### **Contact Details**

Telephone: +61 3 9828 0500

Website: <u>www.vitalifesciences.com.au</u>

Email: <u>enquiries@vitalifesciences.com.au</u>

Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004

